Medical researchers have illuminated a critical player in cholesterol metabolism that acts as a molecular guardian in cells to help maintain cholesterol levels within a safe, narrow range. Known as Nrf1, it both senses and responds to excess cholesterol, and could represent a potential new therapeutic target in a multitude of diseases where cholesterol metabolism is disrupted.
Researchers have tested a genetically-modified soybean oil used in restaurants and found that while it induces less obesity and insulin resistance than conventional soybean oil, its effects on diabetes and fatty liver are similar to those of conventional soybean oil, the major vegetable cooking oil used in the United States, with popularity on the increase worldwide. The study also compares the GM soybean oil to coconut and olive oils.
Patients without calcium buildup in the coronary arteries had significantly lower risk of future heart attack or stroke despite other high risk factors such as diabetes, high blood pressure, or bad cholesterol levels, new research shows.
An experimental drug protected mice from one of the many ills of our cheeseburger and milkshake-laden Western diet -- non-alcoholic fatty liver disease. The drug reversed liver inflammation, injury and scarring in animals fed a high fat, sugar and cholesterol diet. The diet was designed to replicate the Western fast food diet and recreate the features of non-alcoholic fatty liver disease found in people. The research team plans further testing to move it into human trials.
It's well known that calcium is essential for strong bones and teeth, but new research shows it also plays a key role in moderating another important aspect of health -- cholesterol. Scientists have discovered a direct link between calcium and cholesterol, a discovery that could pave the way for new ways of treating high blood cholesterol.
Since frameworks used to identify adults at heightened risk for such complications are a poor fit for kids, the American Academy of Pediatrics now recommends that pediatricians instead focus on clusters of cardiometabolic risk factors that are associated with obesity.
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1). They found that a closely related compound will activate an enzyme, AMPK, triggering a cellular 'recycling' system that helps reduce elevated cholesterol and other accumulated fats in the brains and livers of NPC1 patients, which are hallmarks associated with severe neurological problems.
The US Preventive Services Task Force recommends that primary care professionals individualize the decision to offer or refer adults without obesity who do not have high blood pressure, abnormal cholesterol or blood sugar levels or diabetes to behavioral counseling to promote a healthful diet and physical activity. Existing evidence indicates a positive but small benefit of behavioral counseling for the prevention of cardiovascular disease in this population.
High-density lipoprotein cholesterol (HDL-C) is known as 'good' cholesterol, because HDL particles removes excess cholesterol from arterial walls and transport them back to the liver. A research group has developed a practical test for the ability of HDL to accept cholesterol. This method could help to prevent and monitor cardiovascular disease, and it is simple enough to be used in everyday clinical situations.
The longitudinal study on children and adolescents is unique worldwide. The study shows that cardiovascular risk factors, such as overweight, high blood pressure, low-density lipoprotein (LDL) cholesterol and insulin resistance, are associated with arterial distensibility in adolescence.